Ultime notizie per Vaxcyte (NASDAQ:PCVX) Azioni

Vaxcyte

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Vaxcyte Inc

Wells Fargo analyst Elyse Greenspan maintains Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) with a Equal-Weight and lowers the price target from $406 to $402.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Everest Group, Lowers Price Target to $402

Susquehanna analyst Biju Perincheril maintains AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) with a Positive and lowers the price target from $24 to $21.

Susquehanna Maintains Positive on AES, Lowers Price Target to $21

Wells Fargo analyst Elyse Greenspan maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Equal-Weight and raises the price target from $266 to $268.

Wells Fargo Maintains Equal-Weight on Chubb, Raises Price Target to $268

Wells Fargo analyst Eric Luebchow maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Overweight and lowers the price target from $375 to $365.

Wells Fargo Maintains Overweight on Public Storage, Lowers Price Target to $365

Trading Ideas

ZCAR

Zoomcar Holdings Shares Resume Trade Then Again Halted On Circuit Breaker, This Time To The Downside, Stock Now Up 87.1%

Wells Fargo analyst Chris Carey maintains Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) with a Overweight and raises the price target from $57 to $60.

MNST

Wells Fargo Maintains Overweight on Monster Beverage, Raises Price Target to $60

SoundCloud, the artist-first platform that empowers artists and fans to connect and share through music, and PubMatic, an independent technology company delivering digital advertising's supply chain of the future, announce a new strategic partnership offering SoundCloud's premium advertising inventory across PubMatic's suite of tools and solutions. Combining SoundCloud's extensive reach and engaged user base with PubMatic's advanced advertising solutions, the partnership creates a powerful platform for advertisers to connect with audiences on a global scale.
For the first time, PubMatic will offer SoundCloud global programmatic inventory on all video and display advertising on desktop and mobile app. This integration will give advertisers unprecedented access to SoundCloud's vibrant community of music lovers, offering a unique opportunity to engage with audiences in a meaningful and immersive way. With 400+ million tracks from 40+ million artists across 193 countries, SoundCloud is the largest audio discovery platform in the world. Its global audience of tastemakers, trendsetters, and creators are redefining audio culture. PubMatic will provide expertise, unique monetization opportunities, and access to differentiated demand. The collaboration with SoundCloud aligns with PubMatic's mission to fuel the endless potential of internet content creators.

PUBM

SoundCloud And PubMatic Announce A New Strategic Partnership Offering SoundCloud's Premium Advertising Inventory Across PubMatic's Suite Of Tools And Solutions Creating A Powerful Platform For Advertisers To Connect With Audiences On A Global Scale

Looking into the current session, Air Products &amp; Chemicals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) shares are trading at $305.85, after a 0.08% drop. Over the past month, the stock decreased by 1.39%, but over the past year, it actually increased by 17.74%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1730819874_0.png" alt="Past Year Chart" />

<h3>A Look at Air Products &amp; Chemicals P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 51.67 in the Chemicals industry, Air Products &amp; Chemicals Inc. has a lower P/E ratio of 26.59. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730819874_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Air Products & Chemicals Inc's Price Over Earnings

Wells Fargo analyst Michael Brown maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Underweight and raises the price target from $48 to $51.

Wells Fargo Maintains Underweight on Brookfield Asset Mgmt, Raises Price Target to $51

Wells Fargo analyst Marc Torrente maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Overweight and raises the price target from $157 to $175.

FRPT

Wells Fargo Maintains Overweight on Freshpet, Raises Price Target to $175

Wells Fargo analyst Michael Brown maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Overweight and raises the price target from $67 to $68.

Wells Fargo Maintains Overweight on TPG, Raises Price Target to $68

Wells Fargo analyst Elyse Greenspan maintains Baldwin Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWIN#NASDAQ">BWIN</a>) with a Equal-Weight and lowers the price target from $46 to $43.

BWIN

Wells Fargo Maintains Equal-Weight on Baldwin Insurance, Lowers Price Target to $43

Zoomcar Holdings Shares Resume Trade Then Again Halt On Circuit Breaker To The Upside, Stock Now Up 98%

Wells Fargo analyst Daniel Politzer maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Overweight and lowers the price target from $125 to $122.

WYNN

Wells Fargo Maintains Overweight on Wynn Resorts, Lowers Price Target to $122

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $135 to $145.

GKOS

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $145

Wells Fargo analyst Steven Cahall maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Overweight and raises the price target from $46 to $49.

FOXA

Wells Fargo Maintains Overweight on Fox, Raises Price Target to $49

Housing prices in key battleground states track much closer to conservative-leaning states than liberal ones, according to research from Realtor.com examining real estate trends since the 2020 election.
The analysis of seven swing states – Arizona, Georgia, Michigan, Nevada, North Carolina, Pennsylvania and Wisconsin – found median listing prices averaging $216 per square foot over the past year, well below the $322 average in blue states while hovering just above the $192 seen in red states.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
&#8220;When it comes to home prices, swing states have mirrored red states much more than blue states over the past four years,&#8221; Realtor.com senior economist Ralph McLaughlin was quoted in the report. The data shows swing state prices running 30% to 40% below blue state levels but only 10% to 20% above red states.
Price growth in the much-contested states <a href="https://www.benzinga.com/real-estate/24/05/39112751/home-values-in-swing-states-may-swing-the-2024-presidential-vote">has followed a middle path since 2020</a>. From October 2020, swing state listing prices rose 35% on a square-foot basis, compared to 24% in red states and 40% in blue states. The median listing price in swing states is $399,000, between red states at $371,129 and blue states at $554,321.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
Realtor noted that the price patterns align with broader demographic trends, as swing states typically occupy a middle ground in key metrics like urbanization, education levels and wages. A separate Realtor.com analysis from May found <a href="https://www.benzinga.com/real-estate/24/05/38949118/swing-state-housing-prices-could-sway-2024-election">housing affordability in swing states closely tracking the national average</a>.
Housing policy has become a campaign issue, with Vice President Kamala Harris proposing builder tax credits to create three million new homes and $25,000 in down-payment assistance for first-time buyers. Former President Donald Trump&#8217;s housing proposals center on immigration restrictions and deregulation. His platform includes preventing undocumented immigrants from accessing mortgages. <a href="https://www.benzinga.com/real-estate/24/10/41251977/trump-and-harris-reveal-their-game-plans-to-tackle-skyrocketing-housing-prices-heres-what-has-worked">According to previous Benzinga reporting</a>, the policy could have broader implications for construction costs, as immigrants make up about 20% of the construction workforce.
See Also: ‘Beating the market through ethical real estate investing' —<a href="https://www.benzinga.com/money/invest-with-roots"> this platform aims to give tenants equity in the homes they live in while scoring 17.38% average annual returns for investors – here&#8217;s how to join with just $100</a>
The former president&#8217;s plan also targets zoning regulations, which he identifies as a key barrier to new housing development. His proposed reforms would streamline environmental requirements and permit processes that he says currently impede builders and drive up costs.
According to McLaughlin, if the price growth seen in home prices since the last election matters to voters, "it implies that swing state voters may have federal housing policy on their minds much less than voters in blue states but perhaps a little more than voters in red states,&#8221; he said.
Read Next:
<ul>
<li>Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

'30% Less Than Blue': Swing State Home Prices Align With Red States, Says Realtor.com

Although the broad market has clocked impressive returns in 2024, with the benchmark S&amp;P 500 Index, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), returning more than 20%, legendary investor Warren Buffett has <a href="https://www.benzinga.com/markets/equities/24/10/41294370/warren-buffett-continues-trimming-bank-of-america-position-no-longer-needs-to-report-sales">been a cautious seller</a>.
The Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) chairman notably sold over $100 billion of Berkshire&#8217;s largest holding, Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), capitalizing on the tech giant's valuation and reducing exposure to preserve gains. Additionally, he offloaded substantial portions of Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), trimming Berkshire&#8217;s stake below the critical 10% ownership threshold.
While it is hard to speculate on Buffett's actions, his decision to sell a bank might be tied to an anticipation of lower interest rates. Berkshire still owns about 10% of the stock, but now it is not required to file Form 4 with the SEC within two business days—it can file Form 13F as far as 45 days into 2025.
In addition to a solid orientation around the Fed&#8217;s actions, Buffett's expertise in the insurance industry is noteworthy, as decades of ownership of GEICO give him a vantage point over the market.
Per <a href="https://x.com/KobeissiLetter/status/1852787764720476326">the </a>Kobeissi Letter, he now holds a record $288 billion of U.S. Treasury bills, which is $93 billion more than the Fed.
"Opportunities for investment that are open to the analyst who stresses quantitative factors have virtually disappeared…" Buffett <a href="https://www.ivey.uwo.ca/media/2975913/buffett-partnership-letters.pdf">wrote</a> in May 1969, clarifying the decision to close down his $100 million Buffett Partnership, Ltd. However, in 2024, he's at the helm of one of the largest publicly traded companies in the world.
Buffett's investment preferences are fairly well-known. He seeks companies with a high return on equity (ROE) that demonstrate efficient use of capital and consistent profit margins that indicate financial health.
Furthermore, he favors the "product moat," or competitive advantage, as it creates long-term stability and growth, fends off competition, and sustains profitability. However, a cornerstone of Buffett&#8217;s investing philosophy is his rigorous preference for buying assets at a discount to their intrinsic value.
This preference is so strong that he suspended Berkshire Hathaway's buybacks in the third quarter until the "price is below Berkshire's intrinsic value."
While there are still companies meeting Buffett's criteria, finding them at a bargain has become challenging – particularly at a size that would create a meaningful return for his $325 billion cash pile.
Berkshire Hathaway has returned 22.02% year-to-date.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/11/41726342/can-you-guess-what-asset-the-ultra-wealthy-invest-in-most-heres-a-hint-its-not-stocks">Can You Guess What Asset the Ultra-Wealthy Invest In Most? Here&#8217;s A Hint: It&#8217;s Not Stocks</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

AAPL

Buffett Amasses A $325 Billion Cash Pile, Halts Berkshire Buybacks

Wells Fargo analyst Larry Biegelsen maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Equal-Weight and raises the price target from $187 to $198.

INSP

Wells Fargo Maintains Equal-Weight on Inspire Medical Systems, Raises Price Target to $198

Over the past 24 hours, Chainlink's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) price has risen 3.42% to $10.85. This is contrary to its negative trend over the past week where it has experienced a 7.0% loss, moving from $11.48 to its current price. As it stands right now, the coin's all-time high is $52.70. 
The chart below compares the price movement and volatility for Chainlink over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1730819078_0.png" alt="price_chart" />
The trading volume for the coin has risen 11.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.12%. This brings the circulating supply to 626.85 million, which makes up an estimated 62.68% of its max supply of 1.00 billion. According to our data, the current market cap ranking for LINK is #19 at $6.79 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1730819078_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$LINK

Chainlink Up More Than 3% In 24 hours

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Mizuho Securities analyst Salim Syed has maintained their bullish stance on PCVX stock, giving a Buy rating on September 4. Salim Syed's rating is ...

Vaxcyte's VAX-31 Vaccine: A Strong Buy with Increased Revenue Projections and Substantial Market Potential

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Vaxcyte (PCVX – Research Report). The company's shares closed ye...

TD Cowen Reaffirms Their Buy Rating on Vaxcyte (PCVX)

TimesSquare U.S. Small Cap Growth Strategy Q3 2024 Commentary

ClearBridge Small Cap Growth Strategy Q3 2024 Commentary

ClearBridge Small Cap Strategy Q3 2024 Commentary

Baron Health Care Fund Q3 2024 Shareholder Letter

TD Cowen analyst Tara Bancroft maintained a Buy rating on Vaxcyte (PCVX – Research Report) today. The company's shares closed yesterday at $112.14....

TD Cowen Sticks to Its Buy Rating for Vaxcyte (PCVX)

ACLX

ADUS

AEIS

APOS

ARGNF

ARGX

AVNT

BCAP

BCSF

BIGC

BMYMP

BOOT

BROE

CERT

CFCV

CORT

CSTM

CTRI

CVGW

CWAN

CYRX

DXCM

EVRI

EWCZ

FORM

FOUR

FROG

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

GRDN

HAIN

HELE

HLNE

ICLR

INDI

INFR

INSM

INTA

IRDM

IRTC

ISRG

KVYO

LASR

LNTH

LOAR

LRGE

LUMN

MEDP

MIRM

MODG

MSFT

MTDR

MYPS

MYPSW

MYRG

NARI

PCVX

PGNY

RARE

RDNT

REGN

SEAT

SEATW

SGRY

SLGN

SMCI

STRO

TARS

TGLS

TREX

VRNA

VRNS

VRTX

WSFS

WTFC

WTFCM

WTFCP

XPRO

YLDE

ZETA

Earnings

Press Releases

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Management

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)

General

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Financing

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Comments

Vaxcyte

Notizie

Ultime notizie per Vaxcyte (NASDAQ:PCVX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO